The closing price of CRISPR Therapeutics AG (NASDAQ: CRSP) was $84.22 for the day, down -3.95% from the previous closing price of $87.68. In other words, the price has decreased by -$3.46 from its previous closing price. On the day, 2518644 shares were traded.
Ratios:
Our analysis of CRSP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 17.54 and its Current Ratio is at 17.54. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On December 11, 2023, TD Cowen Downgraded its rating to Underperform which previously was Market Perform but kept the price unchanged to $30.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 20 when Kulkarni Samarth sold 6,370 shares for $79.67 per share. The transaction valued at 507,498 led to the insider holds 194,257 shares of the business.
KASINGER JAMES R. sold 1,913 shares of CRSP for $152,409 on Feb 20. The General Counsel and Secretary now owns 57,371 shares after completing the transaction at $79.67 per share. On Feb 15, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $80.36 each. As a result, the insider received 1,607,177 and left with 187,377 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 7.04B and an Enterprise Value of 5.58B. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.10 while its Price-to-Book (P/B) ratio in mrq is 3.58. Its current Enterprise Value per Revenue stands at 15.09 whereas that against EBITDA is -27.55.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $37.55. The 50-Day Moving Average of the stock is 68.30, while the 200-Day Moving Average is calculated to be 57.95.
Shares Statistics:
CRSP traded an average of 2.75M shares per day over the past three months and 3.09M shares per day over the past ten days. A total of 84.19M shares are outstanding, with a floating share count of 80.85M. Insiders hold about 3.97% of the company’s shares, while institutions hold 64.28% stake in the company. Shares short for CRSP as of Feb 15, 2024 were 14.87M with a Short Ratio of 5.42, compared to 17.04M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.84% and a Short% of Float of 18.07%.
Earnings Estimates
The firm’s stock currently is rated by 17 analysts. On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of $0.74 and a low estimate of -$1.82, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$1.53, with high estimates of -$1.02 and low estimates of -$1.81.
Analysts are recommending an EPS of between -$2.6 and -$7.48 for the fiscal current year, implying an average EPS of -$5.67. EPS for the following year is -$4.26, with 19 analysts recommending between $5.08 and -$7.95.
Revenue Estimates
A total of 21 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $427.9M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $110.1M. In the same quarter a year ago, actual revenue was $371.21M, down -70.30% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $413.4M in the next fiscal year. The high estimate is $3.31B and the low estimate is $40M. The average revenue growth estimate for next year is up 275.50% from the average revenue estimate for this year.
